Filing Flows › Opus Genetics (IRD) › Q2 2026
Opus Genetics (IRD) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Opus Genetics (IRD) reported revenue of $755K for the second quarter 2026 (Q2 2026), -74% from a year earlier and -65% from the quarter before.
Opus Genetics, Q2 2026: revenue $755K (-74% year over year), net loss $8.1M, operating cash flow −$11.9M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $755K | -65% | -74% |
| Operating profit | −$16.5M | — | — |
| Net earnings | −$8.1M | — | — |
| Operating cash flow | −$11.9M | — | — |
What changed
Revenue was $755K in Q2 2026, down 74% year over year and down 65% from the previous quarter.
Operating costs exceeded revenue by $16.5M, an operating margin of -2182.8%. Total costs grew 46% against a revenue fall of 74%. The fastest-growing cost line was Research & development (+86%). The quarter ended with a net loss of $8.1M, narrower than the previous quarter's $65.5M loss. Non-operating items added $8.4M, -104% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$11.9M. Non-cash charges added back $14K of depreciation and $1.4M of share-based compensation. Working capital and other items used $5.3M.
Questions
What was Opus Genetics' revenue in the second quarter 2026?
Opus Genetics (IRD) reported revenue of $755K for the second quarter 2026 (Q2 2026), -74% from a year earlier and -65% from the quarter before.
Source: Opus Genetics 10-Q on SEC EDGAR.